Halozyme Therapeutics | HALO - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.18B 4.3B 2026-03
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
Amarin USD 3K 5K 2024-12
Amgen USD 657M 4M 2026-03
Baxter International USD 58M 14M 2025-09
Cara Therapeutics -89.64M 128.67M 2025-12
Cytokinetics USD 33.34M 3M 2026-03
DBV Technologies USD 461K 323.71K 2025-03
Eli Lilly USD 114.7M 134.3M 2025-09
Esperion Therapeutics USD 22.64M 585K 2025-12
Halozyme Therapeutics USD 5.51M 597K 2026-03
Intrexon USD 2K 5K 2024-06
Ionis Pharmaceuticals USD 17M 1000K 2026-03
MannKind USD 12.43M 1.44M 2026-03
Minerva Neurosciences USD 2.31M 60K 2024-06
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Pfizer USD 671M 40M 2026-03
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
United Therapeutics USD 3.1M 100K 2025-12
Vanda Pharmaceuticals -1.37B 1.97B 2025-12